Narrative review of studies on HIV pre-exposure prophylaxis in Brazil and its implementation in the public health network

Glob Public Health. 2022 Dec;17(12):3721-3734. doi: 10.1080/17441692.2022.2116749. Epub 2022 Sep 6.

Abstract

Objectives: To discuss studies conducted in Brazil relating to PrEP, from 2012 to 2022, based on a narrative review.

Methodology: The databases of the Virtual Health Library/PAHO, portals from Scielo, Scopus, and PubMed, and the descriptors in English and Portuguese 'Pre-exposure to HIV' and 'Brazil' were used, as well as a list of planned/in-progress demonstrative studies. Inclusion criteria consists of articles with fieldwork in Brazil coupled with PrEP in the Brazilian scenario; and articles in English or Portuguese. Articles in which PrEP was not the central theme and the participating Brazilian population did not reside in Brazil were excluded.

Results: 107 papers have been reviewed, 80 articles met the inclusion criteria. The majority participating population was men who have sex with men. 61 studies preceded the implementation of PrEP in Brazil. Studies carried out after implementation (n = 19) deal primarily with the impact of the COVID-19 pandemic.

Conclusions: There was an incipient number of studies on the injectable form of PrEP. Fewer studies included segments with greater difficulties in access, use, and adherence. Despite the issues that circumscribe this prevention technology, literature is consensual on the importance of Brazilian leadership for implementing PrEP.

Keywords: Brazil; HIV; Pre-exposure prophylaxis; biomedical technology; prevention; review.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Brazil / epidemiology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • HIV Infections* / drug therapy
  • HIV Infections* / epidemiology
  • HIV Infections* / prevention & control
  • Homosexuality, Male
  • Humans
  • Male
  • Pandemics
  • Pre-Exposure Prophylaxis*
  • Public Health
  • Sexual and Gender Minorities*

Substances

  • Anti-HIV Agents